Fig. 1: RBAP48 is highly expressed in OSCC patients.

A Western blotting staining showed the expression of RBAP48 in 14 pairs of fresh OSCC tissues. The relative expression (/β-actin) is shown numerically below each band. B qPCR results showed the mRNA expression of RBAP48 in 14 pairs of patients. Student t-test is used, and p < 1e-2**. C Immunohistochemical staining showed the expression of RBAP48 in non-cancerous oral tissues (n = 4) and OSCC tissues of different grades (n = 90). D Immunohistochemical statistical results were obtained using the student t-test between groups. Grade I, (n = 6); Grade II, (n = 25); Grade III, (n = 34); Grade IV, (n = 25). p < 1e-4****, ns indicates no statistical significance. E–I HNSC Patient survival analysis showed the effect of RBAP48 or AR expression on survival in different types of patients from the TCGA database. (E) RBAP48 in all patients; (F) AR in all patients; (G) RBAP48 in AR-positive patients; (H) RBAP48 in AR-negative patients; and (I) RBAP48 in AR-negative patients beyond 900 days.